Literature DB >> 14751469

R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram.

Connie Sánchez1, Mads Kreilgaard.   

Abstract

Escitalopram mediates the serotonin re-uptake inhibitory and antidepressant effect of citalopram racemate. However, recent studies have shown that R-citalopram inhibits the escitalopram-induced increase of extracellular 5-HT levels in the frontal cortex of rats. Here, we investigated the inhibitory effect of R-citalopram on the escitalopram-induced increase of 5-HT neurotransmission at the behavioural [potentiation of 5-hydroxytryptophan (5-HTP)-induced behavioural changes in mice and rats] and functional (increase in serum corticosterone in rats) levels. The effect of escitalopram was inhibited by R-citalopram in all three models, and R-citalopram, given alone, was inactive. The effects were more pronounced using an escitalopram to R-citalopram ratio of 1:4 than ratios of 1:2 and 1:1, suggesting a dose-dependent effect. The ED(50)-value of escitalopram in mouse 5-HTP potentiation studies corresponded to a serum concentration of approximately 50 ng/ml, which can be considered to be in the range of clinically relevant serum concentrations. In conclusion, R-citalopram inhibited the escitalopram-induced increase of 5-HT activity in functional, as well as behavioural, animal models. The mechanism involved in this interaction is currently unknown, but may be related to an improved clinical effect seen with escitalopram in comparison with citalopram.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751469     DOI: 10.1016/j.pbb.2003.12.001

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  14 in total

1.  Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.

Authors:  Peng Zhang; George Cyriac; Theresa Kopajtic; Yongfang Zhao; Jonathan A Javitch; Jonathan L Katz; Amy Hauck Newman
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

2.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

Review 3.  Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.

Authors:  Christian Dolder; Michael Nelson; Andrea Stump
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

Review 4.  Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Authors:  Huailing Zhong; Nasser Haddjeri; Connie Sánchez
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

5.  In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Authors:  N Klein; J Sacher; T Geiss-Granadia; T Attarbaschi; N Mossaheb; R Lanzenberger; C Pötzi; A Holik; C Spindelegger; S Asenbaum; R Dudczak; J Tauscher; S Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-09-06       Impact factor: 4.530

Review 6.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Escitalopram: a review of its use in the management of major depressive disorder.

Authors:  David Murdoch; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy.

Authors:  Ouissame Mnie-Filali; Céline Faure; Laura Lambás-Señas; Mostafa El Mansari; Hassina Belblidia; Elise Gondard; Adeline Etiévant; Hélène Scarna; Anne Didier; Anne Berod; Pierre Blier; Nasser Haddjeri
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

9.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

10.  Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function.

Authors:  Z Nourian; T Mow; D Muftic; S Burek; M L Pedersen; J Matz; M J Mulvany
Journal:  Psychopharmacology (Berl)       Date:  2008-06-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.